Apollomics (APLM) Accounts Payables (2023)
Apollomics' (APLM) quarterly Accounts Payables came in at $947000.0 in Q2 2023.
Powered by 
Analysis
Apollomics (APLM) Accounts Payables (2023) Analysis & Trends
Apollomics (APLM) has reported Accounts Payables for 1 consecutive years, with $947000.0 the latest figure, recorded in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 25.08 Mn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | - |